Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer (V体育ios版)
- PMID: 26575166
- PMCID: PMC4792575
- DOI: 10.18632/oncotarget.6082
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer
Abstract
Ovarian cancer is the most common cause of death among women with gynecologic cancer. We examined molecular profiles of fibroblasts from normal ovary and high-grade serous ovarian tumors to identify novel therapeutic targets involved in tumor progression. We identified 2,300 genes that are significantly differentially expressed in tumor-associated fibroblasts. Fibroblast expression of one of these genes, connective tissue growth factor (CTGF), was confirmed by immunohistochemistry. CTGF protein expression in ovarian tumor fibroblasts significantly correlated with gene expression levels. CTGF is a secreted component of the tumor microenvironment and is being pursued as a therapeutic target in pancreatic cancer. We examined its effect in in vitro and ex vivo ovarian cancer models, and examined associations between CTGF expression and clinico-pathologic characteristics in patients. CTGF promotes migration and peritoneal adhesion of ovarian cancer cells. These effects are abrogated by FG-3019, a human monoclonal antibody against CTGF, currently under clinical investigation as a therapeutic agent. Immunohistochemical analyses of high-grade serous ovarian tumors reveal that the highest level of tumor stromal CTGF expression was correlated with the poorest prognosis. Our findings identify CTGF as a promoter of peritoneal adhesion, likely to mediate metastasis, and a potential therapeutic target in high-grade serous ovarian cancer. These results warrant further studies into the therapeutic efficacy of FG-3019 in high-grade serous ovarian cancer. VSports手机版.
Keywords: CTGF; FG-3019; metastasis; ovarian cancer; tumor microenvironment. V体育安卓版.
Conflict of interest statement
KM-J, BG, RM, DKC, EKC, MDJ, SY, VMH, LMB, CJS, NFH, SG, SCM, MJB and GS declare no conflict of interest. CWW and SMS are employed by FibroGen Inc V体育ios版.
"V体育ios版" Figures




References
-
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
-
- Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–2529. - "VSports注册入口" PubMed
Publication types
- "V体育官网入口" Actions
MeSH terms
- VSports最新版本 - Actions
- "VSports app下载" Actions
- VSports手机版 - Actions
- "V体育官网入口" Actions
- "V体育官网入口" Actions
- "V体育官网入口" Actions
- Actions (V体育2025版)
- VSports注册入口 - Actions
- Actions (VSports手机版)
- Actions (VSports最新版本)
- VSports注册入口 - Actions
- "VSports在线直播" Actions
- Actions (VSports)
- V体育ios版 - Actions
- V体育平台登录 - Actions
Substances
- Actions (VSports最新版本)
- "VSports最新版本" Actions
- "VSports app下载" Actions
- Actions (V体育官网入口)
- "V体育安卓版" Actions
- VSports - Actions
Grants and funding
LinkOut - more resources
Full Text Sources
"V体育官网" Other Literature Sources
Medical
Miscellaneous (VSports手机版)